View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 21, 2021updated 07 Jan 2022 8:50am

Microbix expands QAPs portfolio with new PCR-test control

The multiplex QAP can detect SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus from single sample.

Microbix Biosystems has expanded its Quality Assessment Products (QAPs) portfolio with the introduction of the new Multiplex Respiratory PCR-Test Control.

The single-unit swab-formatted test control is designed to support PCR tests for four most-common global viral infectious respiratory illness, SARS-CoV-2, Influenza A (Flu A), Influenza B (Flu B), and Respiratory Syncytial Virus (RSV).

The company stated that the in-vitro diagnostic (IVD) quality controls can improve the workflow accuracy of multiplex clinical laboratory PCR lab tests, which can detect Flu A, Flu B, SARS-CoV-2, and RSV using a single sample.

Developed using COPAN FLOQSwabs, the Microbix multiplex QAP is branded as REDx FLOQ SARS-CoV-2/Flu A&B/RSV Swab Positive Control.

It comprises all possible PCR targets and uses multiple test platforms.

Currently, the new QAP is available to support quality management systems (QMS) of clinical laboratory that include point-of care workflows and central lab in Canada and the US.

Microbix CEO and president Cameron Groome said: “For optimal patient care and public health management, clinicians and lab directors are rapidly moving to tests that can detect multiple infectious organisms from a single patient-sample.

“Microbix is therefore applying its expertise to develop the leading-edge “multiplex” test controls required to enable and accelerate this very positive evolution.

“I encourage clinical lab directors to reach out to Microbix or one of our nine distributors to sample these important new products for optimally-ensuring the quality of multiplex PCR-tests for respiratory viruses.”

Now, the company’s QAPs portfolio of more than 70 proprietary SKUs, of which 16 QAPs are available as REDx Controls for IVD.

Recently, Applied BioCode received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its CoV-2 Flu Plus Assay that can detect SARS-CoV-2, Flu A, Flu B, and RSV.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network